Abstract
Objectives
The aim of the current study was to evaluate the safety and efficacy of initiation protocol for MiniMed ™ 780G system among an Egyptian cohort of young people living with type 1 diabetes (T1D).
Methods
A prospective single-arm study including 72 participants with T1D. Five days of structured education and training were provided to all users and continuous glucose monitoring (CGM) was initiated on the first day of the training. Users initiated the pump initially in manual mode, with suspend before low feature, for 3 days before shifting to Auto Mode.
Results
The mean HbA1c decreased from 8.72 ± 2.01 % to 6.7 ± 0.4 % (p<0.01). Time in range (70–180 mg/dL) substantially improved from 55.24 % ± 10.35 to 81.7 % ± 5.12 % after spending 84 days in auto mode (p<0.001) with 2.03 % of the time spent below 70 mg/dL. Regarding AHCL compatibility, users spent at least 90 % of time in auto mode.
Conclusions
Young people with T1D successfully initiated the AHCL system, using a tailored structured on-boarding protocol. Structured stepwise initiation protocol and onboarding steps are important prerequisite for participants’ adherence and engagement with the system. Patient education together with optimized pump settings are important predictors of glycemic outcomes.
Acknowledgments
We wish to express our sincere appreciation to all the patients and their families for their cooperation during the study period.
-
Research ethics: The local Institutional Review Board deemed the study exempt from review.
-
Informed consent: Informed consent was obtained from all individuals included in this study.
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: SMA and SEM are employees at Medconsult for medical service. EYI has no conflicts of interest to disclose. The scientific content of the study was not subjected to any bias.
-
Research funding: None declared.
References
1. Miller, KM, Foster, NC, Beck, RW, Bergenstal, RM, DuBose, SN, DiMeglio, LA, et al.. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D exchange clinic registry. Diabetes Care 2015;38:971–8. https://doi.org/10.2337/dc15-0078.Search in Google Scholar PubMed
2. Tauschmann, M, Thabit, H, Bally, L, Allen, JM, Hartnell, S, Wilinska, ME, et al.. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet 2018;392:1321–9. https://doi.org/10.1016/S0140-6736(18)31947-0.Search in Google Scholar PubMed PubMed Central
3. Ly, TT, Nicholas, JA, Retterath, A, Lim, EM, Davis, EA, Jones, TW. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA 2013;310:1240–7. https://doi.org/10.1001/jama.2013.277818.Search in Google Scholar PubMed
4. Bergenstal, RM, Klonoff, DC, Garg, SK, Bode, BW, Meredith, M, Slover, RH, et al.. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013;369:224–32. https://doi.org/10.1056/NEJMoa1303576.Search in Google Scholar PubMed
5. Petrovski, G, Al Khalaf, F, Campbell, J, Day, E, Almajaly, D, Hussain, K, et al.. Glycemic outcomes of advanced hybrid closed loop system in children and adolescents with type 1 diabetes, previously treated with multiple daily injections (MiniMed 780G system in T1D individuals, previously treated with MDI). BMC Endocr Disord 2022;22:80. https://doi.org/10.1186/s12902-022-00996-7.Search in Google Scholar PubMed PubMed Central
6. Silva, JD, Lepore, G, Battelino, T, Arrieta, A, Castañeda, J, Grossman, B, et al.. Real-world performance of the MiniMed™ 780G system: first report of outcomes from 4120 users. Diabetes Technol Therapeut 2022;24:113–9. https://doi.org/10.1089/dia.2021.0203.Search in Google Scholar PubMed PubMed Central
7. Carlson, AL, Sherr, JL, Shulman, DI, Garg, SK, Pop-Busui, R, Bode, BW, et al.. Safety and glycemic outcomes during the MiniMed™ advanced hybrid closed-loop system pivotal trial in adolescents and adults with type 1 diabetes. Diabetes Technol Therapeut 2022;24:178–89. https://doi.org/10.1089/dia.2021.0319.Search in Google Scholar PubMed PubMed Central
8. Medtronic: MiniMed_ 780G. System user guide. https://www.medtronicdiabetes.co.uk/sites/uk/Medtronicdiabetes.co.uk/files/pdf/m003192c021doc_a_final_web_mm780g_ifu_mmol_compressed.pdf (Accessed 24 Jan 2022).Search in Google Scholar
9. Matejko, B, Juza, A, Kieć-Wilk, B, Cyranka, K, Krzyżowska, S, Chen, X, et al.. Transitioning of people with type 1 diabetes from multiple daily injections and self-monitoring of blood glucose directly to MiniMed 780G advanced hybrid closed-loop system: a two-center, randomized, controlled study. Diabetes Care 2022;45:2628–35. https://doi.org/10.2337/dc22-0470.Search in Google Scholar PubMed PubMed Central
10. Seget, S, Rusak, E, Polanska, J, Jarosz-Chobot, P. Prospective open-label, single-arm, single-center follow-up study of the application of the advanced hybrid closed loop system in well-controlled children and adolescents with type 1 diabetes. Diabetes Technol Therapeut 2022;24:824–31. https://doi.org/10.1089/dia.2022.0148.Search in Google Scholar PubMed PubMed Central
11. Arrieta, A, Battelino, T, Scaramuzza, AE, Da Silva, J, Castañeda, J, Cordero, TL, et al.. Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: evidence from 12 870 real-world users. Diabetes Obes Metabol 2022;24:1370–9. https://doi.org/10.1111/dom.14714.Search in Google Scholar PubMed PubMed Central
12. Tubiana-Rufi, N, Schaepelynck, P, Franc, S, Chaillous, L, Joubert, M, Renard, E, et al.. Practical implementation of automated closed-loop insulin delivery: a French position statement. Diabetes Metab 2021;47:101206. https://doi.org/10.1016/j.diabet.2020.10.004.Search in Google Scholar PubMed
13. Battelino, T, Danne, T, Bergenstal, RM, Amiel, SA, Beck, R, Biester, T, et al.. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 2019;42:1593–603. https://doi.org/10.2337/dci19-0028.Search in Google Scholar PubMed PubMed Central
14. Breton, MD, Kanapka, LG, Beck, RW, Ekhlaspour, L, Forlenza, GP, Cengiz, E, et al.. A randomized trial of closed-loop control in children with type 1 diabetes. N Engl J Med 2020;383:836–45. https://doi.org/10.1056/NEJMoa2004736.Search in Google Scholar PubMed PubMed Central
15. Bergenstal, RM, Nimri, R, Beck, RW, Criego, A, Laffel, L, Schatz, D, et al.. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. Lancet 2021;397:208–19. https://doi.org/10.1016/S0140-6736(20)32514-9.Search in Google Scholar PubMed PubMed Central
16. Castañeda, J, Mathieu, C, Aanstoot, HJ, Arrieta, A, Da Silva, J, Shin, J, et al.. Predictors of time in target glucose range in real-world users of the MiniMed 780G system. Diabetes Obes Metabol 2022;24:2212–21. https://doi.org/10.1111/dom.14807.Search in Google Scholar PubMed
17. Messer, LH, Forlenza, GP, Sherr, JL, Wadwa, RP, Buckingham, BA, Weinzimer, SA, et al.. Optimizing hybrid closed-loop therapy in adolescents and emerging adults using the MiniMed 670G system. Diabetes Care 2018;41:789–96. https://doi.org/10.2337/dc17-1682.Search in Google Scholar PubMed PubMed Central
18. Petrovski, G, Al Khalaf, F, Campbell, J, Umer, F, Almajaly, D, Hamdan, M, et al.. One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes. Acta Diabetol 2021;58:207–13. https://doi.org/10.1007/s00592-020-01607-4.Search in Google Scholar PubMed PubMed Central
19. Beato-Víbora, PI, Gallego-Gamero, F, Ambrojo-López, A, Gil-Poch, E, Martín-Romo, I, Arroyo-Díez, FJ. Rapid improvement in time in range after the implementation of an advanced hybrid closed-loop system in adolescents and adults with type 1 diabetes. Diabetes Technol Therapeut 2021;23:609–15. https://doi.org/10.1089/dia.2021.0037.Search in Google Scholar PubMed
20. Weinzimer, SA, Bailey, RJ, Bergenstal, RM, Nimri, R, Beck, RW, Schatz, D, et al.. A comparison of postprandial glucose control in the medtronic advanced hybrid closed-loop system versus 670G. Diabetes Technol Therapeut 2022;24:573–82. https://doi.org/10.1089/dia.2021.0568.Search in Google Scholar PubMed PubMed Central
21. ElSayed, NA, Aleppo, G, Aroda, VR, Bannuru, RR, Brown, FM, Bruemmer, D, et al.. 6. Glycemic targets: standards of care in diabetes-2023. Diabetes Care 2023;46:S97–110. https://doi.org/10.2337/dc23-S006.Search in Google Scholar PubMed PubMed Central
22. de Bock, M, Codner, E, Craig, ME, Huynh, T, Maahs, DM, Mahmud, FH, et al.. ISPAD Clinical Practice Consensus Guidelines 2022: glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes. Pediatr Diabetes 2022;23:1270–6. https://doi.org/10.1111/pedi.13455.Search in Google Scholar PubMed PubMed Central
Supplementary Material
This article contains supplementary material (https://doi.org/10.1515/jpem-2023-0250).
© 2023 Walter de Gruyter GmbH, Berlin/Boston
